WAM
CPRX

Wealthspire Advisors (Maryland)’s Catalyst Pharmaceutical CPRX Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$1M Buy
+337,770
New +$1.32M 0.04% 191

Other funds holding CPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s CPRX Position: Q3 2020 in Review

Wealthspire Advisors (Maryland) opened a new position in Catalyst Pharmaceutical (CPRX) in Q3 2020: 337,770 shares worth $1M. The stake represents 0.04% of the portfolio and ranks #191 among its holdings.

142 funds tracked by Wall St. Rank hold CPRX as of Q3 2020.

  • Wealthspire Advisors (Maryland) held 337,770 shares of Catalyst Pharmaceutical worth $1M as of Q3 2020.
  • Catalyst Pharmaceutical was a new Wealthspire Advisors (Maryland) position in Q3 2020.
  • Catalyst Pharmaceutical made up 0.04% of Wealthspire Advisors (Maryland)'s portfolio in Q3 2020, its #191 holding.
  • 142 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2020.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q3 2020, filed 13 Nov 2020.